Written by: Eric Dallara, RPh
Download Here

The purpose is to provide guidance on side effect prevention and management to minimize treatment interruptions. Diarrhea is a common side effect of Neratinib treatment occurring in 95% of patients in the ExteNET trial on the Neratinib arm.1 The majority 93% of the patients experienced diarrhea in the first month of treatment so there is a great need for prevention and close patient monitoring during the first months of therapy.
Continue reading Neratinib Diarrhea Management

Read More

Written by: Derek Gyori, PharmD and Julianne Orr, PharmD
Download Here

Abemaciclib is an FDA approved Cyclin Dependent Kinase (CDK) 4 and 6 Inhibitor approved for use in hormone receptor (HR) positive and human epidermal growth factor 2 (HER2) negative metastatic breast cancer. Abemaciclib works downstream of the estrogen receptor to halt the progression from the G1 phase to S phase that is a critical step in the replication of cancerous cells.1-3 Abemaciclib has been studied across multiple lines of therapy for metastatic breast cancer and is FDA-approved in combination with an aromatase inhibitor, fulvestrant, and as a single agent. In addition, these studies have shown a lower risk of neutropenia but an increased risk of diarrhea compared to other approved CDK 4&6 inhibitors.1,2,3 Continue reading Management of Abemaciclib Associated Diarrhea

Read More